Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...
Steer clear of a ‘snownado’ if you see one on a cold, sunny day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback